Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03553550 · ClinicalTrials.gov registry record
Role of Circulating Tumor DNA (ctDNA) From LIquid Biopsy in Early Stage NSCLC Resected Lung Tumor Investigation
A clinical trial, sponsored by Addario Lung Cancer Medical Institute.
- Terminated
- Registry status
- 38
- Enrollment target
NCT03553550: Clinical Trial study, sponsored by Addario Lung Cancer Medical Institute.
NCT03553550 is a clinical trial that was terminated before completion, run by Addario Lung Cancer Medical Institute. The registered enrollment target is 38 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03553550 was terminated before completion, sponsored by Addario Lung Cancer Medical Institute.
- TERMINATED
- Registry status
- 38 participants
- Enrollment target
Study Summary
The purpose of this research study is to learn more about changes in cell-free tumor DNA in blood samples, also known as a liquid biopsy, as they relate to treatment and response to treatment.
Primary Outcome
Correlation between ctDNA after surgery and disease-free survival, defined as the time from surgical resection to the earliest event defined as disease recurrence, death or new lung cancer.
Interventions
- OTHER biospecimen collection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2018-06-01 |
| Est. Completion | 2020-11-15 |
Why NCT03553550 stopped before completion
NCT03553550 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 38 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which biospecimen collection is the first listed.
NCT03553550 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03553550 about?
NCT03553550 is a clinical study titled "Role of Circulating Tumor DNA (ctDNA) From LIquid Biopsy in Early Stage NSCLC Resected Lung Tumor Investigation". The purpose of this research study is to learn more about changes in cell-free tumor DNA in blood samples, also known as a liquid biopsy, as they relate to treatment and response to treatment.
What is the current status of trial NCT03553550?
This trial is currently terminated. The enrollment target is 38 participants. The study started on 2018-06-01. Estimated completion is 2020-11-15.
What interventions are being tested in trial NCT03553550?
The interventions under investigation include: biospecimen collection (OTHER).
Who is sponsoring clinical trial NCT03553550?
This trial is sponsored by Addario Lung Cancer Medical Institute, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01684904 · 38 participants · NA
Proton Therapy for Esophageal Cancer
- NCT03310879 · 38 participants · Phase 2
Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-Type Cyclins or Amplification of CDK4 or CDK6
- NCT03896269 · 38 participants · Phase 1
CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
- NCT04085315 · 38 participants · Phase 1
Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI